Cargando…
Efficacy of CMX001 as a Prophylactic and Presymptomatic Antiviral Agent in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans
CMX001, a lipophilic nucleotide analog formed by covalently linking 3-(hexdecyloxy)propan-1-ol to cidofovir (CDV), is being developed as a treatment for smallpox. CMX001 has dramatically increased potency versus CDV against all dsDNA viruses and, in contrast to CDV, is orally available and has shown...
Autores principales: | Rice, Amanda D., Adams, Mathew M., Lampert, Bernhard, Foster, Scott, Lanier, Randall, Robertson, Alice, Painter, George, Moyer, Richard W. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Molecular Diversity Preservation International (MDPI)
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3045966/ https://www.ncbi.nlm.nih.gov/pubmed/21369346 http://dx.doi.org/10.3390/v3020063 |
Ejemplares similares
-
Efficacy of CMX001 as a Post Exposure Antiviral in New Zealand White Rabbits Infected with Rabbitpox Virus, a Model for Orthopoxvirus Infections of Humans
por: Rice, Amanda D., et al.
Publicado: (2011) -
Development of CMX001 for the Treatment of Poxvirus Infections
por: Lanier, Randall, et al.
Publicado: (2010) -
Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus
por: Parker, Scott, et al.
Publicado: (2014) -
Efficacy of therapeutic intervention with an oral ether–lipid analogue of cidofovir (CMX001) in a lethal mousepox model
por: Parker, Scott, et al.
Publicado: (2008) -
Treatment of Vaccinia and Cowpox Virus Infections in Mice with CMX001 and ST-246
por: Quenelle, Debra C., et al.
Publicado: (2010)